key: cord-0766772-bs72pzxr
authors: Curran, J. A.; Dol, J.; Boulos, L.; Somerville, M.; LeBlanc, J.; Barrett, L.; Comeau, J.; Reynolds, B.; McCulloch, H.; MacDonald, M.; Shin, D.; Gallant, A.; Wong, H.; Crowther, D.; Yu, Z.
title: Transmission characteristics of SARS-CoV-2 variants of concern: Rapid Scoping Review
date: 2021-04-25
journal: nan
DOI: 10.1101/2021.04.23.21255515
sha: bd1963ba41f6b918fbe401751eba81ea739ba02a
doc_id: 766772
cord_uid: bs72pzxr

Background: As of March 2021, three SARS-CoV-2 variants of concern (VOC) have been identified (B.1.1.7, B.1.351 and P.1) and been detected in over 111 countries. Despite their widespread circulation, little is known about their transmission characteristics. There is a need to understand current evidence on VOCs before practice and policy decisions can be made. This study aimed to map the evidence related to the transmission characteristics of three VOCs. Methods: A rapid scoping review approach was used. Seven databases were searched on February 21, 2021 for terms related to VOCs, transmission, public health and health systems. A grey literature search was conducted on February 26, 2021. Title/abstracts were screened independently by one reviewer, while full texts were screened in duplicate. Data were extracted using a standardized form which was co-developed with infectious disease experts. A second data extractor verified the results. Studies were included if they reported on at least one of the VOCs and transmissibility. Animal studies and modeling studies were excluded. The final report was reviewed by content experts. Results: Of the 1796 articles and 67 grey literature sources retrieved, 16 papers and 7 grey sources were included. Included studies used a wide range of designs and methods. The majority (n=20) reported on B.1.1.7. Risk of transmission, reported in 15 studies, was 45-71% higher for B.1.1.7 compared to non-VOCs, while R0 was 75-78% higher and the reported Rt ranged from 1.1-2.8. There was insufficient evidence on the transmission risk of B.1.35.1 and P.1. Twelve studies discussed the mechanism of transmission of VOCs. Evidence suggests an increase in viral load among VOCs based on cycle threshold values, and possible immune evasion due to increased ACE2 binding capacity of VOCs. However, findings should be interpreted with caution due to the variability in study designs and methods. Conclusion: VOCs appear to be more transmissible than non-VOCs, however the mechanism of transmission is unclear. With majority of studies focusing on the B.1.1.7 VOC, more research is needed to build upon these preliminary findings. It is recommended that decision-makers continue to monitor VOCs and emerging evidence on this topic to inform public health policy.

, caused by the virus SARS-CoV-2, was declared a worldwide pandemic on March 11 th , 2020 by the World Health Organization (WHO). 1 Since then, it has claimed over 2.45 million lives and 110 million cases have been identified as of February 19 th , 2021. 2 COVID-19 has had a significant impact worldwide, shutting down schools and workplaces, disrupting travel and trade, causing significant mortality and morbidity, particularly among vulnerable populations, and negatively impacting people's mental health. 1, 3 A growing area of interest are Variants of Concern (VOCs). SARS-CoV-2 VOCs result in changes in transmissibility, clinical presentation and severity, or they may have an impact on countermeasures, including diagnostics, therapeutics and vaccines. 3 As of February 20 th , 2021, three VOCs have been identified from 3 different genetic lineages: B.1.1.7 (201/501.1.V1 or 202012/01) in the UK, 4 B.1.351 (20H/501Y.V2) in South Africa, 5 and P.1 (previously known as B.1.1.28.1) in Brazil. 6 The first VOC identified was the B.1.1.7 on December 14 th , 2020, which contained 23 nucleotide substitutions (including eight spike mutations among 14 non-synonymous mutations) 7 and was not phylogenetically related to the SARS-CoV-2 virus. 3 As of March 9, 2021, this variant was found in 111 countries/ territories/ areas. Similarly, the VOCs found in South Africa and Brazil have been detected in 58 and 32 countries, respectively. 8 What remains unknown is the precise degree of impact these variants have on COVID-19 transmission, and the reason for the increased transmissibility, as well as the clinical impact of these strains on severe disease, hospitalization, and death. Previous studies have suggested that VOCs are more transmissible than the original strain, but there is limited evidence related to exactly how much more transmissible they are, due to the heterogeneity in study design and modeling approaches. 3 There is a need to understand more about VOCs as changes to public health recommendations may be required to minimize the further spread of COVID-19.

In order to inform evidence-based recommendations that can reduce VOC-associated risk, health systems need to understand the existing literature and potential impacts of VOCs. Due to the emerging nature of this topic, no current or underway systematic reviews or scoping reviews on the topic were identified. Therefore, the aim of this rapid scoping review is to map the literature related to the transmission characteristics of the SARS-CoV-2 VOCs. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ;  1. How much more transmissible are they? (both in greater susceptibility to infection given exposure and in greater infectiousness once infected)? 2. Why are they more transmissible? (e.g., does the mechanism of transmission vary, can transmission happen with less exposure, and does the timing of peak viral load vary?) 3. What criteria can be used to define new variants of concern? Design Rapid scoping review, following standardized rapid and scoping review guidelines. [9] [10] [11] Methods An information specialist designed a broad, comprehensive search to retrieve all literature related to the VOCs. The electronic database search was executed on February 21 st , 2021 in MEDLINE, Embase, the Cochrane Database of Systematic Reviews (CDSR) and Central Register of Controlled Trials (CENTRAL), Epistemonikos' L·OVE on COVID-19, and medRxiv and bioRxiv concurrently. The electronic database search was followed up by a grey literature search, executed February 26 th to March 1 st , 2021, in a list of specific websites in addition to broader searches of Google and Twitter. Only English-language searches were conducted, but non-English results were considered for inclusion. Full search details are shared in Appendix A.

Evidence specific to VOC transmission was identified and tagged during the screening process. For the purpose of this review, measures of VOC transmission included any of the following: decreases in PCR cycle threshold (Ct) values (as a proxy for viral load), changes in reproduction number, growth rate increases in specific lineages based on genomic data, markers for pathogenesis changes (i.e. In vitro changes in the binding affinity of spike protein receptor binding domain to the ACE2 receptor), changes in neutralization activity of anti-SARS-CoV-2 antibodies, and gene detection drop-outs like S-gene target failure (SGTF) in diagnostic assays.

Animal studies were excluded. Studies that only reported predictive modelling data were excluded. Reviews, overviews, and news articles that presented no original data were excluded, but checked for references to primary studies, which were screened for inclusion. Title/abstract screening was completed by a single reviewer in Covidence; full text screening was completed by one reviewer and verified by a second. The data extraction form was designed in consultation with infectious disease specialists and microbiologists; data were extracted by one reviewer and verified by a second. Critical appraisal was not conducted, but will be a feature of future reports. The final report was reviewed by infectious disease experts and microbiologists engaged as content experts on our team.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 25, 2021. ; https://doi.org/10.1101/2021.04.23.21255515 doi: medRxiv preprint

The search retrieved 1796 electronic database records and 67 grey literature records, of which 16 and 7 were included, respectively (see Appendix B: PRISMA Flow Diagram). Of the 23 sources identified, 13 were pre-prints, three were published in peer reviewed journals, and seven were grey literatures sources. Three sources report on P.1 6, 12, 13 , three sources report on B.1.351 [13] [14] [15] and 20 sources report on B.1.1.7 4, 13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] (Table 1) . One source reported on both the SA VOC and UK VOC 15 and one reported on all three. 13 Most studies (n=13) report on data from the UK, three studies reported on data from the United States 20,23,25 , two from Brazil, 6,12 and one each from Israel, 17 Wales, 32 and Zambia. 14 Two studies reported on data from multiple countries. 13, 15 Limitations As this was a rapid scoping review, formal critical appraisal of included studies was omitted. The next update of this report will include critical appraisal of this and other literature identified in the updated search. Of note, most included sources have not been peer-reviewed. Considering this and the fact that this is an emerging field of research, findings should be interpreted with caution until more evidence becomes available. We also identified significant heterogeneity between studies in terms of analysis and reporting, testing approaches for the VOCs, and sample size. A separate search for VOC definitions was not executed due to time constraints. Data informing question 3 was extracted from studies included for question 1 and 2.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 25, 2021 .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. 

Research Square

To determine the genetic epidemiology study of emergence of P.1 variant of concern Generated 250 SARS-CoV-2 high-quality whole-genome sequences from individuals living in 25 municipalities of the Amazonas state between 16th March 2020 and 13th January 2021 P.1 Brazil P.1 prevalence in the Amazonas state increased from 0% in November 2020 to 73% in 1st-15th January 2021. There was also a significant (Mann-Whitney test, P < 0.0001) lower median score in URT samples from P.1-infected (Ct = 19.8) compared with non-P.1infected (Ct = 23.0) subjects, indicating that viral load was ~ 10fold higher in P.1 infections than in non-P.1 infections.

Jan 12, 2021 medRxiv To report on the evolution and emergence of the P.1 variant of concern Analysis of 436 SARS-CoV-2 RT-qPCR positive results from a testing laboratory in Manaus from 1 November 2020 to 9 January 2021. Molecular clock analysis, transmissibility and immune evasion

It cannot yet be determined if P.1 infection is associated with increased viral loads or a longer duration of infection.

.

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint To address question 1, we searched for data related to risk of transmission, changes in transmission, and reproduction number. We describe the findings by each VOC. When interpreting these findings, it is important to consider that transmission can be reflected in a number of ways, including reproduction number, VOC growth rate, and gene detection drop-outs like SGTF. Each measure used has limitations and potential biases depending on how it was used, and the population assessed. 17 They also reported that B.1.1.7 was 45% more transmissible than the wild type in Israel based on an analysis of over 300,000 RT-PCR tests from the general community and a nursing home sample between December 6 th , 2020 and February 10 th , 2021. There was no evidence of variation in risk of transmission based on age, with the exception of a population of individuals >60 years, approximately 2 weeks post-first . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ;  vaccination, which showed a decline. Munitz et al. found that prior to the impact of the national lockdown in Israel, the R t of B.1.1.7 was as high as 1.71 (95% CI:1.59-185) compared to 1.12 (95% CI: 1.10-1.15) for the wild type. 17 In the UK, Zhao et al. estimated that B.1.1.7 is 52% (95% CI: 46, 58) more transmissible than the wild type based on 94,934 SARS-CoV-2 sequencing data and COVID-19 surveillance data from August 1 st to December 31 st , 2020 as available in the public databases released by GISAID and World Health Organization. 26, 28 In a December 18 th , 2020 NERVTAG report, they found that the B.1.1.7 VOC growth rate was 71% (95% CI: 65%-75%) higher than other variants. 30 Similarly, the Public Health England December 21 st , 2020 report found the growth factors as 1.47 (95% CI: 1.34-1.59) between October 25 th and December 5 th , 2020 using SGTF among PCR positives as a proxy for B.1. 1.7. 28 According to Public Health England, B.1.1.7 VOC was found to be significantly associated with higher reproduction number. 28 25 Walker et al. reported that the growth rate in SGTF positives (proxy for B.1.1.7) generally exceeded the decline in non-SGTF SARS-CoV-2 positive cases in the UK, by an average of 6%, suggesting an overall increase in rate of VOC infections, not just replacement. 16 There was no evidence of variation based on age.

Grabowski et al. reported that B.1.1.7 started expanding in the UK during week 43 (<5 cases were reported per week) and by week 51, reached 57% of all sequenced genomes based on GISAID data collected between week 43 and week 51 of 2020 (October 19 th to December 20 th , 2020). 15 This was compared to the proportion of 20A.EU1 strain, characterized by A222V substitution in spike protein which constituted more than 65% of genomes sequenced in England in November 2020, which dropped from 86% to 35% and other genomes dropped from 31% to 8%. 15 Grabowski . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ; 1.89-2.77), where the lower bound is the estimate between weeks 44-51 and the higher bounds for weeks 43-47 in the UK. Graham 4 Leung et al. found that the R 0 of B.1.1.7 was 75% (95% CI: 70-80%) higher than that of the wildtype strain (501N) in a UK sample. 19 Hunter et al. found that from mid-lockdown in November to the first week in December, most variants declined but the new variant increased quite dramatically during that same time. 22 The estimated R t value for the East of England, London and South East regions for the novel variant was 1. 

The majority of information available on transmission related to VOCs is on the B.1.1.7 variant. Based on limited research, B.1.1.7 VOC transmission risk ranges from 45-71% higher. The R 0 of B.1.1.7 compared to non-VOC ranges from 75-78% higher, while the reported R t values range from 1.1-2.8. Additionally, it appears there is an additive transmission effect, where it is not only replacing previous infections, but also associated with an increase in the number of infections. However, further work is needed to clarify and expand on this, recognizing the possibilities of inherent biases in study design or data captured.

According to the WHO as of March 9 th , 2021, B.1.351 has been reported in 58 countries across all six WHO regions. 8

In terms of transmission risk, Grabowski et al. reported that the R t for B.1.351 was 1.55 (95%CI: 1.43-1.69), meaning that it is 55% more transmissible than the wild type strain. 15 They also reported that the relative advantage ratio of B.1.351 to other strains was at a weekly rate of 1.58 (95%CI: 1.45-. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ;  1.72). The CDC reported that the detection of the B.1.351 variant coincided with a rapid rise in confirmed cases in Zambia, establishing an epidemiologic linkage between COVID-19 outbreaks in Zambia and South Africa. 14 However, they did not report more specifics on the rate of transmission. 13 While the WHO report stated that the B.1.351 variant was more transmissible, this was not supported by their references as Davies et al. 4 reports on B.1.1.7 and Wibmer et al. 33 does not seem to report on transmissibility.

While there have been no reported findings related to greater susceptibility to infection given exposure to B.1.351 nor in greater infectiousness once infected, the WHO report cited a case study that found a person was re-infected with the B.1.351 strain after recovery from an earlier COVID-19 infection and the clinical presentation was more severe. 34 As this was a letter to the editor case study that did not report on transmission beyond a single case, it did not meet our eligibility criteria to include as an original source.

While B.1.351 might be more transmissible based on findings from one study in the UK, limited recommendations or conclusions can be drawn at this time.

According to the WHO as of March 9 th , 2021, P.1 has been reported in 32 countries across all six WHO regions. 8 Faria et al. used dynamic modelling that integrates genomic and mortality data, to estimate that P.1 may be 1.4 to 2.2 times more transmissible and 25-62% more likely to evade protective immunity of previous infections on non-VOCs. Naveca et al. reported P.1 was first detected on December 4 th , 2020 in Manaus, Brazil and displayed an extremely rapid increase in prevalence up to January 2021. 6 In particular, through sequencing all SARS-CoV-2 positive samples between November 1 st , 2020 and January 31 st , 2021, they found that none of the samples genotyped by real-time PCR before December 16 th had the NSP6 deletion, indicating a very low prevalence of P.1 before mid-December 2020 in Amazonas. Using both genomic sequencing and real-time PCR testing, P.1 prevalence in the Amazonas state increased from 0% in November 2020 (n = 0/88), to 4% in December 1 st to 16 th , 2020 (n = 2/54), 45% in December 17 th to 31 st , 2020 (n = 104/232), and 73% in January 1 st to 15 th , 2021 (n = 119/162).

No data was found on greater susceptibility to infection given exposure or on greater infectiousness once infected for the P.1 VOC.

While P.1 might be more transmissible based on findings from two studies in Brazil, limited recommendations or conclusions can be drawn at this time due to a paucity of data.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ;

To address question 2, we searched for data related to the mechanism of transmission (e.g., peak viral load, transmission in relation to exposure). It is worth noting that many studies assessed viral load through analysis of RT-qPCR Ct values from laboratory testing of respiratory samples. Ct values are only a proxy measure of peak viral load. Ct measure can vary based on a number of factors including instrument, type of specimen (e.g upper or lower respiratory tract), timing of sample related to onset of symptoms or exposure, and storage or transport of specimen. 30, [35] [36] [37] 

Several studies have focused on measuring viral load as an indicator of increased transmissibility of B.1.1.7. In general, we identified variation across studies in terms of methods and outcomes. A large surveillance study conducted in the UK between September 28 th , 2020 and January 2 nd , 2021, with monthly PCR tests of nose and throat swabs on children 2-15 years old (n=372,626) identified an increase in SGTF, including during periods of lockdown when non-SGTF strains were stable or decreasing. 16 However, there was no evidence that viral loads were lower in those who were SGTF positive and there was no difference in growth between children and adults counter to other studies which suggest B.1.1.7 is particularly adapted to transmit more in children. Further, there was no evidence to suggest that increased infection rates were mediated by higher viral loads (lower Ct). 16 To assess the surveillance testing program in nursing homes in Israel, Munitz et al. analyzed primary data from RT-PCR samples collected between December 6 th , 2020 and February 10 th , 2021 to compare Ct threshold values of 60+ age groups in the general community and nursing homes. Findings revealed significantly lower Ct values in the community in comparison to nursing homes residents with matching age groups (p,0.001). 17 These results were deemed to support the success of the surveillance program as viral load was understood to drive transmission. Kidd et al. analyzed a dataset of 641 SARS-CoV-2 positive results of respiratory samples from October 25 th to November 25 th , 2020 and identified a significantly higher number of SGTF samples were associated with a higher viral load, although similar viral loads were seen in non-SGTF samples. 18 Golubchik et al. sequenced RT-QPCR CoV-2 positive samples from four UK Lighthouse Laboratories and identified 88 SARS-CoV-2 positive samples with the spike protein N501Y amino acid substitution (proxy of any of the 3 circulating VOCs) taken between October 31 st , 2020 and November 13 th , 2020. They identified approximately 3-fold higher median viral load in the 501Y containing samples compared with wildtype N501 samples. Results remained significant when controlled for batch but not Lighthouse laboratory. 24 The December 18 th report by NERVTAG concluded that there were insufficient data to draw any conclusions on underlying mechanisms of increased transmissibility, including increased viral load. 30 As the number of B.1.1.7 infections have grown rapidly, studies have also examined if the location of the 501Y mutation within the spike protein receptor binding domain (RBD) and increased affinity for the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ;  ACE2 receptor might provide a biological hypothesis for greater infectivity. Liu et al. tested the affinity of B.1.1.7.201/501Y.V1 for ACE2 receptor and found that the mutated spike protein RBD with a N501Y mutation had a ~10 times greater affinity for ACE2 than the wild-type N501-RBD in vitro. This provides a possible hypothesis for potentially explaining the increased rate of infections in the United Kingdom. 20 Studies have also examined how changes in social contact patterns correlate with changes in transmission of B.1.1.7. Davies et al. used Google mobility and social contact survey data from September 2020 to December 2020 to examine the influence of social contact patterns on transmission. A national lockdown was imposed between November 5 th , 2020 and December 2 nd , 2020, however, no differences in social interactions were identified between regions of high and low B.1.1.7 prevalence. The authors suggest the lack of correlation between social contact patterns and transmission may be related to evolution of the virus. 4 The length of infection has also been examined as a means for understanding transmissibility of B. The CDC reports that B.1.351 might be associated with higher viral loads and contain a spike protein that might hinder antibody binding which could lessen naturally developed immunity, but this was not substantiated by primary data included in this review. 14 P. 1 Faria et al. noted that similar to other VOCs, P.1 is associated with increased binding to the human ACE2 receptor, but they were unable to determine if P.1 infection was associated with increased viral loads or longer infection. 12 Naveca et al. used real-time RT-PCR Ct values as a proxy of viral load and compared samples of P.1 positive and P.1 negative collected at the similar time from onset of symptoms. Analysis revealed a significantly (p<0.0001) lower median score in P.1 positive (Ct=19.8) compared with P.1 negative (Ct=23.8) indicating approximately 10-fold higher viral load in P.1 infections, suggesting that P.1 infected adult individuals are more infectious than those with non-P.1 viruses. These findings hold true when comparing Ct values for adult (18-59 years) men (P=0.005), adult (18-59 years) women (p<0.0001) and older (>59 years) women (p=0.0149) but not in older (>59 years) men (p=0.4624). 6 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ;  Summary While it is difficult to draw conclusions about the underlying mechanisms of VOC transmissibility from the existing data, there is some evidence to suggest there may be an increase in viral load using RT-PCR Ct values as a proxy measure. A few studies have also proposed that VOCs might evade immune system response through increased ACE2 binding. We identified variation in methods, outcome measures and reporting across included studies and limited evidence related to the underlying mechanisms of transmissibility, particularly on P.1 and B.1.351.v

A report from Public Health England first identified an emerging SARS-CoV-2 variant as Variant Under Investigation (VUI 202012/01) on December 8 th , 2020. The nomenclature of this variant was later changed to Variant of Concern on December 18 th , 2020, after an expert review and risk assessment. 28 The following components have been used to describe a VOC in the 23 included sources:

1. Phylogenetically distinct from other SARS-CoV-2 variants 12,28 2. Mutations of biological significance 4,12 3. Rapid spread, dominance and/or selective advantage over other variants 4, 12, 28, 30 On February 25 th , 2021, the WHO released an updated working definition for SARS-CoV-2 Variants of Interest (VOI) and Variants of Concern (VOC). 13 A VOI is named as such if:

"It is phenotypically changed compared to a reference isolate or has a genome with mutations that lead to amino acid changes associated with established or suspected phenotypic implications" AND "has been identified to cause community transmission/multiple COVID-19 cases/clusters or has been detected in multiple countries" OR "is otherwise assessed to be a VOI by WHO CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 25, 2021. ;  compared to non-VOC ranges from 75-78% higher. Additionally, it appears there is an additive transmission effect, where it is not only replacing previous infections, but also associated with an increase in the number of infections. While there is heterogeneity in the data, the evidence points towards an increase in transmissibility in VOCs. Further work is needed to clarify and expand on this. While B.1.351 and P.1 might be more transmissible based on findings from one study each, limited recommendations or conclusions can be drawn at this time due to a paucity of data. Additionally, currently no data is available on greater susceptibility to infection given exposure or in greater infectiousness once infected for all the VOC, with one case study noting a possibility of re-infection for the B.1.351 VOC.

With respect to understanding why VOCs are more transmissible, it is difficult to draw conclusions from existing data on the underlying mechanisms of increased transmission due to heterogeneity of included studies and an overall dearth of evidence, particularly on P.1 and B.1.351. There appears to be a lack of consistent findings related to whether viral loads (approximated by Ct values) are higher in VOCinfected individuals, and whether the period of RT-PCR positivity may be extended, with variation depending on the population sampled, specimen type, testing method and timing. Further it is unclear if the VOC spike protein interferes with the immune response through increased ACE2 binding. In vitro and animal data have been excluded from this review and may contribute to findings in future reports.

While several studies and governing bodies have reported key characteristics of VOCs, there is variation among the terminology. The WHO released a working definition for both VOIs and VOCs in February 2021, 13 but this may continue to evolve as more evidence on circulating variants emerges.

• Continued monitoring of circulating and emerging VOCs at a regional, national and international level is important. It is also important that this information is shared with national and international stakeholders and health organizations in a timely manner. • Continued routine systematic sequencing of SARS-CoV-2 and VOCs with a focus on using a standardized testing approach to facilitate data comparison across multiple locations. • As VOCs appear to be as transmissible if not more than the non-VOC strains, existing public health guideline remain important. Any lifting public health measures, including re-opening or "returning to normal", should be done cautiously. • If synergized and shared, information about public health precautions and restrictions can be included as a dimension in associative or epidemiological studies, which will be important to interpret VOC data in the local context. • While current evidence is mixed, this may be related to differences in measurement approaches, including Ct and R as surrogate measures of viral load and transmission, respectively, across studies. Additionally, Ct measure can vary based on a number of factors including instrument, type of specimen (e.g. upper or lower respiratory tract), timing of sample . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 25, 2021. ; https://doi.org/10.1101/2021.04.23.21255515 doi: medRxiv preprint related to onset of symptoms or exposure, and storage or transport of specimen. Future surveillance studies should report more details on characteristics of testing, if available.

• Further research is needed on the biological relevance of mutations observed in VOCs, as well as the pathophysiology of why transmission is higher, as the mechanism is still not well understood.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 25, 2021 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 25, 2021 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 25, 2021. ; https://doi.org/10.1101/2021.04.23.21255515 doi: medRxiv preprint

WHO Declares COVID-19 a Pandemic

Coronavirus Pandemic (COVID-19)

WHO. WHO | SARS-CoV-2 Variants

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. medRxiv

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv

COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations -SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology

World Health Organization, Alliance for Health Policy and Systems Research

Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv

Weekly epidemiological update

Detection of B.1.351 SARS-CoV-2 Variant Strain -Zambia

SARS-CoV-2 Variant of Concern 202012/01 has about twofold replicative advantage and acquires concerning mutations. medRxiv

Increased infections, but not viral burden, with a new SARS-CoV-2 variant. medRxiv

The rise of SARS-CoV-2 variant B.1.1.7 in Israel intensifies the role of surveillance and vaccination in elderly. medRxiv

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

The basis of a more contagious 501Y.V1 variant of SARS-COV-2. bioRxiv

The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility. medRxiv

The Impact of the November 2020 English National Lockdown on COVID-19 case counts. medRxiv

Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. medRxiv

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein. medRxiv

Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. medRxiv

Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: an early data-driven analysis

Analysis of transmissibility based on genomics

Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv

NERVTAG. NERVTAG meeting on SARS-CoV-2 variant under investigation

NERVTAG. Update note on B.1.1.7 severity

Technical Advisory Group Variant of Concern (VOC 202012/01) and Education in Wales

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv

Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report

Values: What They Are and How They Can be Used

Nasal-Swab Testing Misses Patients with Low SARS-CoV-2 Viral Loads

OR 2019ncov OR 19ncov OR covid19* OR covid OR 'sars-cov-2' OR 'sarscov-2' OR 'sars-cov2' OR sarscov2 OR 'severe acute respiratory syndrome coronavirus 2' OR 'severe acute respiratory syndrome corona virus 2'):ti,ab,kw,de,tt,oa,ok 4 ((new OR novel OR '19' OR '2019' OR wuhan OR hubei OR china OR chinese) NEAR/3 (coronavirus* OR 'corona virus*' OR betacoronavirus* OR cov OR hcov)):ti,ab,kw,de,tt,oa,ok 5 ((coronavirus* OR 'corona virus*' OR betacoronavirus*) NEAR/3 (pandemic* OR epidemic* OR outbreak* OR crisis)):ti,ab,kw,tt,oa,ok 6 ((wuhan OR hubei) NEAR/5 pneumonia):ti,ab

(((uk or united kingdom or england or english or britain or british or kent) adj3 (variant* or voc or vui)) or "b117" or "20i 501yv1" or "variant of concern 202012 01" or "voc 202012 01" or "variant under investigation in december 2020" or "variant under investigation 202012 01" or "vui 202012 01").ti,ab,kw,kf. 8 (((south africa* or sa) adj3 (variant* or voc or vui)) or "b1351" or "501v2" or "501yv2" or "20h 501yv2" or "20c 501yv2").ti,ab,kw,kf. 9((brazil* adj3 (variant* or voc or vui)) or "p1" or "b11281" or ((mutation* or spike*) adj3 (k417t or e484k or n501y))).ti,ab,kw,kf. 10 ((mutation* or spike*) adj3 d614g).ti,ab,kw,kf. 11 or/7-10 12 6 #4 and #8 10 (ncov* or 2019ncov or 19ncov or covid19* or covid or "sars-cov-2" or "sarscov-2" or sarscov2 or "severe acute respiratory syndrome coronavirus 2" or "severe acute respiratory syndrome corona virus 2"):ti,ab,kw 11 ((new or novel or "19" or "2019" or wuhan or hubei or china or chinese) near/3 (coronavirus* or "corona virus*" or betacoronavirus* or cov or hcov)):ti,ab,kw Appendix B: PRISMA Diagram